Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014902 | 0.83 | CA2 (0.53) | CA2MAOBPSMB5PSMB8CYP17A1 | |
| SCHEMBL1271520 | 0.82 | CA2 (0.59) | CA2MAOBPSMB5PSMB8CYP17A1 | |
| SCHEMBL1271517 | 0.82 | CA2 (0.55) | CA2MAOBPSMB5PSMB8CYP17A1 | |
| SCHEMBL16924213 | 0.81 | CA2 (0.55) | CA2MAOBPSMB5PSMB8CYP17A1 | |
| SCHEMBL4021660 | 0.80 | CA2 (0.50) | CA2MAOBPSMB5PSMB8CYP17A1 | |
| SCHEMBL4022925 | 0.79 | CA2 (0.49) | CA2MAOBPSMB5PSMB8CYP17A1 | |
| SCHEMBL6511944 | 0.79 | MAOB (0.63) | CA2MAOBPSMB5PSMB8CYP17A1 | |
| SCHEMBL734117 | 0.78 | CA2 (0.48) | CA2MAOBPSMB5PSMB8CYP17A1 | |
| SCHEMBL4014881 | 0.78 | CA2 (0.48) | CA2MAOBPSMB5PSMB8CYP17A1 | |
| SCHEMBL4022553 | 0.78 | CA2 (0.48) | CA2MAOBPSMB5PSMB8CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872044-B2 | (thio)amide benzofuran compounds containing phosphonic, phosphinic, sulfonic, sulfamic, or carboxy acid groups; for example [benzofuran-3-yl-(naphthalen-2-ylcarbamoyl)-methyl]-phosphonic acid; treating inflammatory or serine protease mediated disorders such as allergic rhinitis, asthma and heart failure | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-18 | — | — | US | disclosed |
| EP-1085540-B1 | SOLID ELECTROLYTIC CAPACITOR AND METHOD FOR PREPARING THE SAME | SHOWA DENKO KK (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-20080096844-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| US-6466421-B1 | Solid electrolytic capacitor and method for producing the same | SHOWA DENKO K.K. (JP) | 2002-10-15 | — | — | US | disclosed |
| US-6344966-B1 | ELECTRICALLY CONDUCTING POLYMER LAYER CONTAINS AS A DOPANT AN ANION OF(1) ALKOXY-SUBSTITUTED NAPHTHALENESULFONATE, (2) A HETEROCYCLIC SULFONATE, OR (3) AN ANION OF AN ALIPHATIC POLYCYCLIC COMPOUND | SHOWA DENKO K.K. (JP) | 2002-02-05 | — | — | US | disclosed |
| EP-1085540-A1 | SOLID ELECTROLYTIC CAPACITOR AND METHOD FOR PREPARING THE SAME | Showa Denko K K (JP) | 2001-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096844-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, PRSS1 | CA2 330/4885MAOB 899/4885PSMB5 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.